ASCL1-regulated DARPP-32 and t-DARPP stimulate small cell lung cancer growth and neuroendocrine tumour cell proliferation
Related Experiment Video
Updated: Dec 19, 2025
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Sk Kayum Alam1, Li Wang1, Yanan Ren1
1The Hormel Institute, University of Minnesota, Austin, MN, USA.
Background:
Small cell lung cancer (SCLC) is the most aggressive form of lung cancer, and new molecular insights are necessary for prognostic and therapeutic advances.
Methods:
Dopamine and cAMP-regulated phosphoprotein, Mr 32000 (DARPP-32) and its N-terminally truncated splice variant, t-DARPP, were stably overexpressed or ablated in human DMS-53 and H1048 SCLC cells. Functional assays and immunoblotting were used to assess how DARPP-32 isoforms regulate SCLC cell growth, proliferation, and apoptosis. DARPP-32-modulated SCLC cells were orthotopically injected into the lungs of SCID mice to evaluate how DARPP-32 and t-DARPP regulate neuroendocrine tumour growth. Immunostaining for DARPP-32 proteins was performed in SCLC patient-derived specimens. Bioinformatics analysis and subsequent transcription assays were used to determine the mechanistic basis of DARPP-32-regulated SCLC growth.
Results:
We demonstrate in mice that DARPP-32 and t-DARPP promote SCLC growth through increased Akt/Erk-mediated proliferation and anti-apoptotic signalling. DARPP-32 isoforms are overexpressed in SCLC patient-derived tumour tissue, but undetectable in physiologically normal lung. Achaete-scute homologue 1 (ASCL1) transcriptionally activates DARPP-32 isoforms in human SCLC cells.
Conclusions:
We reveal new regulatory mechanisms of SCLC oncogenesis that suggest DARPP-32 isoforms may represent a negative prognostic indicator for SCLC and serve as a potential target for the development of new therapies.
Insights
Dopamine and cAMP-regulated phosphoprotein (DARPP-32) and its variant t-DARPP promote aggressive small cell lung cancer (SCLC) growth. These isoforms may serve as negative prognostic indicators and therapeutic targets for SCLC.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Small cell lung cancer (SCLC) is highly aggressive, necessitating novel molecular targets for improved prognostics and therapeutics.
- Understanding the molecular drivers of SCLC is crucial for developing effective treatment strategies.
Purpose of the Study:
- To investigate the role of Dopamine and cAMP-regulated phosphoprotein (DARPP-32) and its splice variant, t-DARPP, in SCLC oncogenesis.
- To determine if DARPP-32 isoforms can serve as prognostic markers or therapeutic targets in SCLC.
Main Methods:
- Overexpression and ablation of DARPP-32 isoforms in human SCLC cell lines (DMS-53, H1048).
- Functional assays, immunoblotting, and orthotopic mouse xenograft models to assess tumor growth, proliferation, and apoptosis.
- Immunostaining of patient-derived SCLC tissues and bioinformatics analysis to elucidate regulatory mechanisms.
Main Results:
- DARPP-32 and t-DARPP significantly promote SCLC growth in mice via Akt/Erk-mediated proliferation and anti-apoptotic signaling.
- DARPP-32 isoforms are overexpressed in SCLC tumors but not in normal lung tissue.
- ASCL1 (Achaete-scute homologue 1) was identified as a transcriptional activator of DARPP-32 isoforms in SCLC cells.
Conclusions:
- DARPP-32 isoforms are key regulators of SCLC growth and oncogenesis.
- Elevated DARPP-32 expression may indicate a poor prognosis for SCLC patients.
- DARPP-32 isoforms represent promising therapeutic targets for novel SCLC treatments.
